Acute Hepatitis C Virus Infection Treated with Daclatasvir/Sofosbuvir in a 9-Year-Old Boy

Abstract

The present study includes a case report of a 9-year-old boy who came to our center with jaundice, elevated liver enzymes, and palpable liver. He was treated with ursodeoxycholic acid, but no improvement in symptoms was seen. Reverse transcription polymerase chain reaction and liver biopsy were positive for hepatitis C virus. He was treated with daclatasvir/sofosbuvir for 3 months. Daclatasvir/sofosbuvir might be effective against the treatment of hepatitis in children, with no report of remission and minimal side effects.

Keywords

hepatitis C - ursodeoxycholic acid - RT-PCR - liver enzymes

Note

Consent was not obtained to publish the case report. This report does not contain any personal information that could lead to the identification of the patient.

Availability of Data and Material

Data sharing is not applicable to this article as no data sets were generated or analyzed during the current study.

Publikationsverlauf

Eingereicht: 21. Oktober 2021

Angenommen: 08. Mai 2022

Artikel online veröffentlicht:
15. September 2022

• References

• 1 Squires JE, Balistreri WF. Hepatitis C virus infection in children and adolescents. Hepatol Commun 2017; 1 (02) 87-98
• 2 Mahmud S, Akbarzadeh V, Abu-Raddad LJ. The epidemiology of hepatitis C virus in Iran: systematic review and meta-analyses. Sci Rep 2018; 8 (01) 150
• 3 Lohia P, Jinjuvadia R, May E. Profound jaundice in a patient with acute hepatitis C. BMJ Case Rep 2013; 2013: bcr2013200233
• 4 Li DK, Chung RT. Overview of direct-acting antiviral drugs and drug resistance of hepatitis C virus. Methods Mol Biol 2019; 1911: 3-32
• 5 Lagging M, Wejstål R, Norkrans G. et al; Swedish Consensus Group. Treatment of hepatitis C virus infection for adults and children: updated Swedish consensus recommendations. Infect Dis (Lond) 2016; 48 (04) 251-261
• 6 Maughan A, Ogbuagu O. Pegylated interferon alpha 2a for the treatment of hepatitis C virus infection. Expert Opin Drug Metab Toxicol 2018; 14 (02) 219-227
• 7 Merat S. et al. The efficacy of 12 weeks of sofosbuvir, daclatasvir, and ribavirin in treating hepatitis C patients with cirrhosis, genotypes 1 and 3. Hepat Mon 2017; 17 (01) e44564
• 8 Agha RA, Franchi T, Sohrabi C, Mathew G, Kerwan A. SCARE Group. The SCARE 2020 guideline: updating consensus Surgical CAse REport (SCARE) guidelines. Int J Surg 2020; 84: 226-230
• 9 Collins LF, Chan A, Zheng J. et al. Direct-acting antivirals improve access to care and cure for patients with HIV and chronic HCV infection. Open Forum Infect Dis 2017; 5 (01) ofx264-ofx264
• 10 Li C, Hu J. A case report of sofosbuvir and daclatasvirto treat a patient with acute hepatitis C virus genotype 2 monoinfection. Medicine (Baltimore) 2018; 97 (15) e0416
• 11 Rockstroh JK, Bhagani S, Hyland RH. et al. Ledipasvir-sofosbuvir for 6 weeks to treat acute hepatitis C virus genotype 1 or 4 infection in patients with HIV coinfection: an open-label, single-arm trial. Lancet Gastroenterol Hepatol 2017; 2 (05) 347-353
• 12 Welzel TM, Petersen J, Herzer K. et al. Daclatasvir plus sofosbuvir, with or without ribavirin, achieved high sustained virological response rates in patients with HCV infection and advanced liver disease in a real-world cohort. Gut 2016; 65 (11) 1861-1870
• 13 Abdel Ghaffar TY, El Naghi S, Abdel Gawad M. et al. Safety and efficacy of combined sofosbuvir/daclatasvir treatment of children and adolescents with chronic hepatitis C genotype 4. J Viral Hepat 2019; 26 (02) 263-270
• 14 Yakoot M, El-Shabrawi MH, AbdElgawad MM. et al. Dual sofosbuvir/daclatasvir therapy in adolescent patients with chronic hepatitis C infection. J Pediatr Gastroenterol Nutr 2018; 67 (01) 86-89
• 15 El-Shabrawi MH, Abdo AM, El-Khayat HR, Yakoot M. Shortened 8 weeks course of dual sofosbuvir/daclatasvir therapy in adolescent patients, with chronic hepatitis C infection. J Pediatr Gastroenterol Nutr 2018; 66 (03) 425-427